心脏衰竭骑士的骑士们
Chiara Mozzini1, Mauro Pagani1
1Department of Medicine, ASST Mantova, C. Poma Hospital, Mantova, Italy.
Current problems in cardiology
|May 27, 2023
概括
新的心力衰竭 (HF) 治疗侧重于四种药物类别和新型药物. 韦里西瓜特显示出有前途的结果,而肌肉酶激活剂和抑制剂正在研究改善HF结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 翻译医学是一种翻译医学.
背景情况:
- 2021年欧洲心脏病学会的指导方针从顺序转向了四个支柱的心力衰竭 (HF) 管理方法,减少喷射小部分的心力衰竭 (HFrEF).
- 最近的临床试验已经引入了超越已建立的四大支柱的新型治疗剂.
研究的目的:
- 审查HFrEF新兴的分子疗法,检查它们的疗效和作为未来治疗的潜力.
- 为了突出显示新的药剂,如 vericiguat,omecamtiv mecarbil,aficamten,和 mavacamten.
主要方法:
- 审查最近的临床试验数据和HFrEF的指南更新.
- 对针对心力衰竭的不同机制的新型药物类别的分析.
主要成果:
- 维瑞西瓜特是一种可溶性瓜尼酸环酶刺激剂,在住院的HFrEF患者中显示出有效性.
- 奥梅卡姆蒂夫 (Omecamtiv mecarbil) (心脏髓激活剂) 减少了HF事件和心血管死亡.
- 阿菲卡门特和马瓦卡门特 (心脏肌肉素抑制剂) 通过降低超收缩性来改善过度缩性心肌病的功能能力.
结论:
- 像 vericiguat,omecamtiv mecarbil,aficamten和 mavacamten 这样的新药代表了HFrEF治疗的有希望的进步.
- 这些新兴疗法提供了新的策略,以改善心力衰竭患者的治疗结果.
相关概念视频
01:30Heart Failure VII: Nursing Interventions
121
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
121
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:21Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
01:28Mitral Regurgitation IV: Nursing Management
51
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
51
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17